webinar register page

Bristol Myers Squibb/Celgene Myeloma Drugs: Patient-Safety or Profit Motive?
An investigative look into one of the biggest mysteries of the 340B program.

More than a thousand 340B-eligible hospitals do not have access to Revlimid - a widely used drug from pharmaceutical manufacturer Bristol Myers Squibb/Celgene to treat the incurable cancer multiple myeloma. Due to stringent safety rules, only two dozen specialty pharmacies and fewer than 250 providers can buy, prescribe, and dispense Revlimid and similar medications. Very few 340B hospitals and pharmacies are able to get these drugs, limiting patient access and causing covered entities to miss out on hundreds of millions of dollars a year in 340B savings.

On the heels of a groundbreaking 6-part investigative series, the 340B Report's Publisher & CEO Ted Slafsky and Editor in Chief Tom Mirga join Caravan Health’s Founder & Executive Chair Lynn Barr for an interactive webinar to discuss why 340B providers cannot access pricing on profitable drug products from Bristol Myers Squibb/Celgene. Attendees will learn about fraud allegations, congressional oversight, and hear about efforts to recoup these missing savings.

**This webinar is intended for covered entities only. All non-covered entities will not be permitted to attend.

Oct 5, 2021 01:00 PM in Eastern Time (US and Canada)

* Required information